Physician profile
Timothy G Doyle
NPI 1043281991
$378.49
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2023: $19.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $149.69 | 2019 | |
| Novo Nordisk INC | $54.39 | 2019-2023 | |
| Abbott Laboratories | $43.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.66 | 2019 | |
| Sunovion Pharmaceuticals INC. | $33.07 | 2019 | |
| Lilly USA, LLC | $23.76 | 2019 | |
| Amgen INC. | $22.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.